Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$142.77 USD

142.77
24,945,343

-6.89 (-4.60%)

Updated Aug 27, 2026 04:00 PM ET

After-Market: $141.04 -1.73 (-1.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nalak Das headshot

Wall Street Regains Momentum on Vaccine Hopes: 5 Top Picks

by Nalak Das

Investment in momentum stocks with a favorable Zacks Rank may be fruitful in the near term. These include Fulgent Genetics (FLGT), II-VI (IIVI), General Motors (GM), Flagstar Bancorp (FBC) and Lear (LEA).

Sanghamitra Saha headshot

Small-Cap Value ETF (FYT) Hits a New 52-Week High

by Sanghamitra Saha

This small-cap value ETF has hit a new 52-week high. Are more gains in store?

Mark Vickery headshot

Markets Begin Pricing In Post-Pandemic Reality

by Mark Vickery

This is the second consecutive Monday where excellent news on Covid-19 vaccine potential got the trading week off on the right foot.

Zacks Equity Research

Energy ETFs Jump on Coronavirus Vaccine News

by Zacks Equity Research

Energy stocks have benefited from vaccine optimism

Daniel Laboe headshot

Vaccine Hopes Push Markets To Frothy Levels: Stocks To Watch

by Daniel Laboe

There is now a more defined light at the end of this pandemic tunnel. Still, we are not out of the woods yet.

Zacks Equity Research

Moderna's (MRNA) Coronavirus Vaccine Shows 94.5% Efficacy Rate

by Zacks Equity Research

Moderna's (MRNA) COVID-19 vaccine candidate mRNA-1273 proves its vaccine efficacy of 94.5% in the late-stage COVE study. The stock appreciates in pre-market trading following this news.

John Blank headshot

Vaccine Data Propels Stocks: Global Week Ahead

by John Blank

Moderna said in a Phase 3 trial, which enrolled 30K patients, its vaccine demonstrated 94.5% efficacy. The trial included "many high-risk or elderly" people. Furthermore, their vaccine can be stored a temperatures a commercial freezer can likely supply, easing distribution concerns.

David Borun headshot

The S&P Hits a New High and the Dow Eyes Its Own 30K Milestone

by David Borun

Stocks continue to rally broadly on more good vaccine news, even as Covid-19 cases and deaths spike.

Zacks Equity Research

Positive Developments on COVID-19 Treatment Front

by Zacks Equity Research

Positive Developments on COVID-19 Treatment Front.

Mark Vickery headshot

Moderna (MRNA) Covid Drug Proves 94.5% Efficacy

by Mark Vickery

The company now intends on filing for emergency authorization in the United States. Shares are up for MRNA 14% in the early market on the news.